Mesenchymal stem/stromal cells as adjuvant therapy in COVID-19-associated acute lung injury and cytokine storm: Importance of cell identification.
World J Stem Cells
; 14(3): 264-266, 2022 Mar 26.
Article
in English
| MEDLINE | ID: covidwho-1792158
ABSTRACT
Theoretically, mesenchymal stem cells (MSCs) are very promising as adjuvant therapy to alleviate coronavirus disease 2019 (COVID-19)-associated acute lung injury and cytokine storm. Several published studies, which used MSCs to alleviate COVID-19-associated acute lung injury and cytokine storm, reported promising results. However, the evidence came from a case report, case series, and clinical trials with a limited number of participants. Therefore, more studies are needed to get robust proof of MSC beneficial effects.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Prognostic study
Language:
English
Journal:
World J Stem Cells
Year:
2022
Document Type:
Article
Affiliation country:
Wjsc.v14.i3.264
Similar
MEDLINE
...
LILACS
LIS